Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic

A drug’s EU launch seldom becomes more important than its U.S. rollout from a market opportunity perspective, but that’s exactly what’s happening to Amarin’s fish oil-derived heart drug Vascepa.

Amarin has started prepping sales reps in Germany for the planned launch of Vascepa—to be sold under the brand Vazkepa in Europe—before the end of September, the company said Tuesday. By mid-second quarter, it expects to have about 150 marketing staffers in place for product and disease awareness programs.